{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse%2FRecurrence&page=81", "query": { "condition": "Relapse/Recurrence", "page": 81 }, "page_size": 10 }, "pagination": { "page": 81, "page_size": 10, "total_count": 3146, "total_pages": 315, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse%2FRecurrence&page=82&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse%2FRecurrence&page=80&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-10T07:09:18.600Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03739619", "title": "Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Hodgkin Lymphoma", "Refractory Hodgkin Lymphoma", "Classical Hodgkin Lymphoma", "Hodgkin Lymphoma" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2018-11-26", "completion_date": "2025-04-30", "has_results": true, "last_update_posted_date": "2025-08-06", "last_synced_at": "2026-11-10T07:09:18.600Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03739619" }, { "nct_id": "NCT07711483", "title": "GLORY: Glofit-GemOx With Liso-Cel For Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "B-cell Lymphomas", "Relapsed/Refractory Large B-cell Lymphoma", "Large B-cell Lymphoma" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Glofitamab", "type": "DRUG" }, { "name": "Gemcitabine & oxaliplatin", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Lymphodepleting chemotherapy", "type": "DRUG" }, { "name": "LISOCABTAGENE MARALEUCEL", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2026-09-15", "completion_date": "2032-03-15", "has_results": false, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-11-10T07:09:18.600Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07711483" }, { "nct_id": "NCT05634369", "title": "A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pediatric Sarcoma, Refractory", "Pediatric Sarcoma, Relapsed" ], "interventions": [ { "name": "GEM/DOX + TGFBi expanded NK cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Nationwide Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "2 Years to 40 Years" }, "enrollment_count": 50, "start_date": "2022-11-14", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-11-10T07:09:18.600Z", "location_count": 22, "location_summary": "South Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 19 more", "locations": [ { "city": "South Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05634369" }, { "nct_id": "NCT01200329", "title": "High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Palifermin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "12 Years to 70 Years" }, "enrollment_count": 81, "start_date": "2011-06", "completion_date": "2018-12-06", "has_results": true, "last_update_posted_date": "2019-12-16", "last_synced_at": "2026-11-10T07:09:18.600Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01200329" }, { "nct_id": "NCT00619645", "title": "Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "busulfan", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 8, "start_date": "2007-06", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2018-01-10", "last_synced_at": "2026-11-10T07:09:18.600Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00619645" }, { "nct_id": "NCT01871675", "title": "Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Chronic Lymphocytic Leukemia", "Non-Hodgkin Lymphoma", "T-cell Lymphoma" ], "interventions": [ { "name": "IPI-145", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2013-05", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2016-07-11", "last_synced_at": "2026-11-10T07:09:18.600Z", "location_count": 4, "location_summary": "Denver, Colorado • Sarasota, Florida • Oklahoma City, Oklahoma + 1 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01871675" }, { "nct_id": "NCT01132573", "title": "Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Leukemias of Ambiguous Lineage", "Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Untreated Adult Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "entinostat", "type": "DRUG" }, { "name": "clofarabine", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 27, "start_date": "2010-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-07-17", "last_synced_at": "2026-11-10T07:09:18.600Z", "location_count": 4, "location_summary": "Aurora, Colorado • Denver, Colorado • Baltimore, Maryland", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01132573" }, { "nct_id": "NCT03886831", "title": "A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory Advanced Solid Tumors", "Relapsed/Refractory Diffuse Large B-cell Lymphoma", "Relapsed/Refractory Myelodysplasia", "Relapsed/Refractory Myelofibrosis", "Adenoid Cystic Carcinoma", "Relapsed/Refractory Mantle Cell Lymphoma", "Relapsed/Refractory Acute Myeloid Leukemia", "Refractory Chronic Myelomonocytic Leukemia" ], "interventions": [ { "name": "PRT543", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Prelude Therapeutics Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 232, "start_date": "2019-02-11", "completion_date": "2022-11-16", "has_results": false, "last_update_posted_date": "2023-03-28", "last_synced_at": "2026-11-10T07:09:18.600Z", "location_count": 23, "location_summary": "Gilbert, Arizona • San Francisco, California • Newark, Delaware + 19 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03886831" }, { "nct_id": "NCT03707457", "title": "Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Glioblastoma Multiforme" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Anti-GITR Monoclonal Antibody MK-4166", "type": "DRUG" }, { "name": "IDO1 inhibitor INCB024360", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2019-03-22", "completion_date": "2020-06-18", "has_results": false, "last_update_posted_date": "2020-07-02", "last_synced_at": "2026-11-10T07:09:18.600Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03707457" }, { "nct_id": "NCT03930953", "title": "A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "CC-99282", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Tafasitamab", "type": "DRUG" }, { "name": "Valemetostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 438, "start_date": "2019-05-20", "completion_date": "2028-02-09", "has_results": false, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-11-10T07:09:18.600Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Tampa, Florida + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03930953" } ] }